Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (March 2023)
15 slides from Revive Therapeutics's investor presentation, March 2023
Slide 1: A Specialty Life Sciences Company
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation March 2023 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Specialty life sciences company FDA approved Phase 3 clinical Developing novel Psilocybin focused on repurposing drugs trial for Bucillamine in the and Cannabidiol therapeutics Psilocybin for rare disorders and treatment of COVID-19 for various CNS and infectious dise
Slide 4: Pharmaceutical Strategy
PHARMACEUTICAL STRATEGY Clinical development of Targeting Rare Novel Uses, Targeting FDA Psilocybin, Disorders and Formulations, and Designations: Cannabidiol and Infectious Diseases, Delivery System Orphan, Fast track, Bucillamine Neurological Disorders, Breakthrough Mental Health and therapy Liver
Slide 5: Patent Portfolio
PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Non-Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Drug Delivery System US 95
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Psychedelics and Rare Disorders Stage of Product Indication Regulatory Status Development Infectious Diseases Phase 3 FDA approved Bucillamine COVID-19 (COVID-19) for Phase 3 Substance Use CTA with University of Psilocybin Disorder Phase 1/2 Wisconsin M
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Received FDA approval for Focus on Bucillamine in Revive’s clinical history Bucillamine scientific FDA Phase 3 clinical trial the treatment of with Bucillamine rationale as an intervention for COVID-19 infectious diseases for COVID-19 (see Appendix) • Phase 3 study is
Slide 8: Psychedelics Opportunity
PSYCHEDELICS OPPORTUNITY Acquired Psilocin Pharma Corp. • Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis • Worked with Xanthic Bio Pharma and Green Growth Brands • Developed water Soluble THC and CBD products (Beverages, effervescent tablets) Microneedle Patch and Psilocy
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics and cannabinoids DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), imp
Slide 10: Strategic Partners
STRATEGIC PARTNERS Psilocybin Oral Thin Film Microneedle Patch MDMA Collaboration Delivery Collaboration Collaboration License of cannabidiol for treatment Psilocybin Biosynthesis R&D partnership of Autoimmune Hepatitis Collaboration Psychedelic pharma © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL
Slide 11: Expected Milestones
EXPECTED MILESTONES 1H 2023 • Finalize FDA pathway of Phase 3 • Phase 1/2 study for Psilocybin study and potential unblinding of (Methamphetamine Use data Disorder) at University of Wisconsin • Schedule of DSMB meeting for • Manufacturing of Psilocybin oral COVID-19 Phase 3 study primary thin film f
Slide 12: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 13: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R V V T F (OTCQB) | 31R (Frankfurt) CAD $0.49 / $0.04 CAD ~ $22,000,000 Share Price Capital Structure CAD $0.06 (March 22, 2023) 356,237,674 common shares © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 13
Slide 14: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 15: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (March 2023) on 6ix